Yasmin Karimi

Has grant

University of Michigan

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Contemporary Use and Real-World Efficacy of Osteoclast Inhibitors on Skeletal Related Events and Mortality in Patients with Metastatic Breast Cancer

Open Date: 2019-01-01

Close Date: 2020-01-01

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (3)

Megan McNerney

University of Chicago

UNITED STATES

View details

Shannon Carty

University of Michigan

UNITED STATES

View details

Victoria R Nachar

University of Michigan Rogel Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yasmin Karimi

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (15)

ABCL-1119: Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Patients With Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis

ABCL-370: Novel Analysis of 3-Year Results From the Pivotal EPCORE NHL-1 Study: Outcomes in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) and Complete Response (CR) at 2 Years With Epcoritamab Monotherapy

IBCL-378: Epcoritamab Monotherapy Demonstrates Deep and Durable Responses at 3-Year Follow-Up in Patients With Relapsed/Refractory Follicular Lymphoma

IBCL-770: Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Tafasitamab With Rituximab + Lenalidomide in Second-Line or Later Follicular Lymphoma

POSTER: ABCL-1119 Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Patients With Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis

POSTER: ABCL-370 Novel Analysis of 3-Year Results From the Pivotal EPCORE NHL-1 Study: Outcomes in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) and Complete Response (CR) at 2 Years With Epcoritamab Monotherapy

POSTER: IBCL-378 Epcoritamab Monotherapy Demonstrates Deep and Durable Responses at 3-Year Follow-Up in Patients With Relapsed/Refractory Follicular Lymphoma

POSTER: IBCL-770 Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Tafasitamab With Rituximab + Lenalidomide in Second-Line or Later Follicular Lymphoma

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?

Development and Use of Natural Language Processing for Identification of Distant Cancer Recurrence and Sites of Distant Recurrence Using Unstructured Electronic Health Record Data

Reply to Ritzwoller et al

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.

Collaborators (3)

Megan McNerney

Shannon Carty

Victoria R Nachar

Make your next move.